AGIOS PHARMACEUTICALS, INC. Proceeds from Sale of Available-for-sale Securities
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Proceeds from Sale of Available-for-sale Securities of $13.00 million for the 12-month period ending 2011-12-31, per its 10-K filed 2014-03-18.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2014-03-18
- AGIOS PHARMACEUTICALS, INC. proceeds from sale of available-for-sale securities for fiscal 2011 was $13.00M.
| Period end | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|
| 2011-12-31 | $13.00M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |